Should I buy Arrowhead Pharmaceuticals (ARWR) stock or is it too late?

Arrowhead Pharmaceuticals · Health Care · price $58

See the full Arrowhead Pharmaceuticals (ARWR) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: HC Wainwright & Co. — 71% of its targets hit on this sector (248 calls tested). It aims for $120 (+106 %), call made on September 2, 2026, maturing on September 2, 2027 (42 d ago).

The 6 reliable analysts $112+92 %

The 5 other firms $98+69 %

How to read it: the 6 reliable firms are not filtered by optimism — 6 aim above the price, 0 below, hence their $112 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Arrowhead Pharmaceuticals

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Cantor Fitzgerald	62 %	+73.5 %	8	$47 -19%
HC Wainwright & Co.	50 %	+63.3 %	26	$120 +106%
Chardan Capital	42 %	+59.7 %	19	$115 +98%
RBC Capital	42 %	+47.0 %	12	$100 +72%
B. Riley Securities	50 %	+42.0 %	10	$123 +112%
Piper Sandler	50 %	+38.0 %	10	$126 +117%

In short — Should you invest in Arrowhead Pharmaceuticals? Is it too late, still worth it? Analysts are overwhelmingly positive (82% buy, median target $108, i.e. +86%), and the most reliable on ARWR targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

82% of analysts rate it a buy (Buy consensus, 11 ratings) — a sign of market conviction.
Median price target $108, i.e. +86% from the current price ($58).
The most reliable firm on ARWR, HC Wainwright & Co. (50% hit rate, 26 scored calls), targets $120 (call made on September 1, 2026, maturing on September 1, 2027) (+106%) in its most recent call, and $85 (call made on December 2, 2025, maturing on December 2, 2026) (+46%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 11 ratings, 2 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on ARWR

Median target $108 (+86%) · 11 ratings · Buy consensus

Strong Buy00%

Buy982%

Hold218%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Arrowhead Pharmaceuticals now?

We won't decide for you. The facts: 82% of analysts rate it a buy, median target $108 (+86%), and HC Wainwright & Co. (most reliable on ARWR, 50%) targets $120. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Arrowhead Pharmaceuticals?

Not according to analysts: the median target ($108) is still +86% above the current price ($58) (most reliable on ARWR: HC Wainwright & Co., 50%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Arrowhead Pharmaceuticals still worth investing in?

It depends on the gap between the price ($58) and its estimated value: analysts target $108 on median (+86%), with 82% buys (most reliable on ARWR: HC Wainwright & Co., 50%). Cross-check with their real reliability on ARWR and the cautions above. Information, not advice.

What's the main risk in buying ARWR?

The consensus is not unanimous: of 11 ratings, 2 are neutral.

→ Go deeper: the full Arrowhead Pharmaceuticals profile (consensus, analyst reliability, price target, performance).